Ventas (VTR) Up 2.2% Since Last Earnings Report: Can It Continue?
Werte in diesem Artikel
A month has gone by since the last earnings report for Ventas (VTR). Shares have added about 2.2% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Ventas due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since Then?It turns out, estimates review have trended downward during the past month.VGM ScoresAt this time, Ventas has a subpar Growth Score of D, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions has been net zero. Notably, Ventas has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerVentas is part of the Zacks REIT and Equity Trust - Other industry. Over the past month, Healthpeak (DOC), a stock from the same industry, has gained 0.4%. The company reported its results for the quarter ended December 2024 more than a month ago.Healthpeak reported revenues of $697.99 million in the last reported quarter, representing a year-over-year change of +26.1%. EPS of $0.01 for the same period compares with $0.46 a year ago.For the current quarter, Healthpeak is expected to post earnings of $0.46 per share, indicating a change of +2.2% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.3% over the last 30 days.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Healthpeak. Also, the stock has a VGM Score of D.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ventas, Inc. (VTR): Free Stock Analysis Report Healthpeak Properties, Inc. (DOC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Ventas und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Ventas
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Ventas
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Ventas Inc.
Analysen zu Ventas Inc.
Datum | Rating | Analyst | |
---|---|---|---|
03.09.2019 | Ventas Equal Weight | Barclays Capital | |
04.05.2018 | Ventas Market Perform | BMO Capital Markets | |
22.03.2017 | Ventas Hold | SunTrust | |
21.11.2016 | Ventas Neutral | Mizuho | |
13.07.2016 | Ventas Hold | Argus Research Company |
Datum | Rating | Analyst | |
---|---|---|---|
04.05.2018 | Ventas Market Perform | BMO Capital Markets | |
06.07.2016 | Ventas Buy | Mizuho | |
05.04.2016 | Ventas Buy | Mizuho | |
03.03.2016 | Ventas Buy | Mizuho | |
15.01.2016 | Ventas Market Perform | BMO Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
03.09.2019 | Ventas Equal Weight | Barclays Capital | |
22.03.2017 | Ventas Hold | SunTrust | |
21.11.2016 | Ventas Neutral | Mizuho | |
13.07.2016 | Ventas Hold | Argus Research Company | |
02.05.2016 | Ventas Equal Weight | Barclays Capital |
Datum | Rating | Analyst | |
---|---|---|---|
24.05.2010 | Ventas "underperform" | Robert W. Baird & Co. Incorporated |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Ventas Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen